The Garvan Institute of Medical Research has collaborated with Roche Sequencing to develop new technologies for targeted epigenomic analysis using DNA sequencing.

Genomics is a field that focuses on realising the potential use of sequencing information in patient diagnosis and treatment.

As part of the terms of the two-year discovery agreement, the companies will work together to develop new methods to accurately analyse regions of the epigenome.

Garvan Institute executive director professor John Mattick said: "This is an excellent example of collaboration between a leading-edge company and research institute in the development of advanced technology for genetic analysis, which will empower more research into human biology and disease, and lead to many translational opportunities."

Garvan will provide its genomics expertise and infrastructure, while Roche NimbleGen, part of the Roche Sequencing unit, will provide products for target enrichment.

Roche’s SeqCap target enrichment system will be used by Garvan scientists to advance their research in epigenetic influences on human diseases.

Roche Sequencing unit head Tom Albert said: "In addition to our recent investments in sequencing platform technologies, our research team is working closely with key opinion leaders to advance sequencing applications of current and future technologies.

"This collaboration with the Garvan Institute illustrates the potential of SeqCap target enrichment products in additional sequencing applications for epigenetic research."

Image: Garvan has joined forces with Roche to develop new technologies for targeted epigenomic analysis. Photo: courtesy of the Garvan Institute.